1-5 of 5
Wenduo He
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A first-in-human, phase I/II, open-label, multicenter, dose escalation and expansion study of lbl-034, a conditionally activated bispecific antibody targeting GPRC5D and CD3 with a 2:1 format, in patients with relapsed/refractory multiple myeloma

Free
Xuelin Dou, Yuping Zhong, Wanhong Zhao, Ling Qin, Xin Du, Aijun Liao, Zhongjun Xia, Chunyan Sun, Songfu Jiang, Dongping Huang, Haitang Xie, Liangming Ma, Jishi Wang, Fengyan Jin, Guifang Ouyang, Yanhong Tong, Min Dong, Bing Xu, Wenduo He, Shengli Cai, Jin Lu
Journal: Blood
Blood (2025) 146 (Supplement 1): 91.
https://doi.org/10.1182/blood-2025-91
Published: 2025
Journal Articles

Population pharmacokinetics (popPK) and exposure-response (ER) analyses of lbl-034, a potent GPRC5D T cell engager in patients with relapsed/refractory multiple myeloma

Free
Bin Fan, Juanjuan Wu, Leijun Hu, John Yang, Chengtao Lu, Wenduo He, Ting Lv, Xiaoqiang Kang, Shengli Cai
Journal: Blood
Blood (2025) 146 (Supplement 1): 6824.
https://doi.org/10.1182/blood-2025-6824
Published: 2025
Journal Articles

Pharmacokinetics, pharmacodynamics, and biomarkers of lbl-034, a GPRC5D-targeted T cell engager, in a first-in-human phase Ⅰ/Ⅱ study in relapsed/refractory multiple myeloma

Free
Bin Fan, Juanjuan Wu, Jin Lu, Xuelin Dou, Wenduo He, Chengtao Lu, Ting Lv, Yilan Mei, Xiaoqiang Kang, Shengli Cai
Journal: Blood
Blood (2025) 146 (Supplement 1): 4070.
https://doi.org/10.1182/blood-2025-4070
Published: 2025
Journal Articles

Proof of concept and mechanistic evaluation of lbl-034, a potent GPRC5D-targeting T cell engager with affinity-optimized, sterically engineered anti-CD3 arm, in a multiple myeloma xenograft mouse model

Free
Juanjuan Wu, Bin Fan, Wenduo He, Chengtao Lu, Yilan Mei, Xiaofan Hou, Xiaoqiang Kang, Shengli Cai
Journal: Blood
Blood (2025) 146 (Supplement 1): 2155.
https://doi.org/10.1182/blood-2025-2155
Published: 2025
Journal Articles

GB261, an Fc-Function Enabled and CD3 Affinity De-Tuned CD20/CD3 Bispecific Antibody, Demonstrated a Highly Advantageous Safety/Efficacy Balance in an Ongoing First-in-Human Dose-Escalation Study in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma

Free
Yuqin Song, Zengjun Li, Ling Li, Zhengzi Qian, Keshu Zhou, Lei Fan, Peter Tan, Pratyush Giri, Zhiming Li, Melita Kenealy, Jie Jin, Wei Liu, Shafqat Inam, Yan Xie, Xia Guo, Wenduo He, Raymond Xu, Tong Li, Jun Zhu
Journal: Blood
Blood (2023) 142 (Supplement 1): 1719.
https://doi.org/10.1182/blood-2023-188444
Published: 2023